Alamar Biosciences to present at BofA Securities 2026 Healthcare Conference on May 12

Alamar Biosciences, a leader in Precision Proteomics focused on early disease detection, will present at the BofA Securities 2026 Healthcare Conference in Las Vegas on May 12. The company will showcase its proprietary NULISA™ technology and ARGO™ HT System, which enable ultra-sensitive detection of protein biomarkers. This presentation highlights Alamar's ongoing efforts to advance early disease diagnosis and attract investor interest. A live webcast will be available on the company's investor website.